|
| [ На главную ] -- [ Список участников ] -- [ Правила форума ] -- [ Зарегистрироваться ] |
| On-line: |
| Клуб болельщиков "Торпедо" Владимир / / cgXQxqsguXOTNQ |
| Страницы: 1 |
|
| Автор | Сообщение |
|
Duncan Гость |
Добавлено: 20-06-2022 17:49 |
|
this post is fantastic eskalith drug classification The company confirmed its full-year outlook. Group sales in 2013 are expected to increase in line with last year's sales growth, at constant exchange rates. Core EPS is targeted to grow ahead of sales. In 2013, the company expects to further increase its dividend. |
| Страницы: 1 |
|
| Клуб болельщиков "Торпедо" Владимир / / cgXQxqsguXOTNQ |